These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections. Gavaghan V; Miller JL; Dela-Pena J Infection; 2023 Apr; 51(2):475-482. PubMed ID: 36201152 [TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study. Oliva A; Liguori L; Covino S; Petrucci F; Cogliati-Dezza F; Curtolo A; Savelloni G; Comi M; Sacco F; Ceccarelli G; Viscido A; Alessandri F; Raponi G; Pugliese F; Mastroianni CM; Venditti M Eur J Clin Microbiol Infect Dis; 2024 Jun; 43(6):1149-1160. PubMed ID: 38634975 [TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020. Kohira N; Hackel MA; Oota M; Takemura M; Hu F; Mizuno H; Sahm DF; Yamano Y J Glob Antimicrob Resist; 2023 Mar; 32():181-186. PubMed ID: 36513320 [TBL] [Abstract][Full Text] [Related]
8. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence. Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal. Gijón D; García-Castillo J; Fernández-López MC; Bou G; Siller M; Calvo-Montes J; Pitart C; Vila J; Torno N; Gimeno C; Cruz H; Ramos H; Mulet X; Oliver A; Ruiz-Garbajosa P; Canton R Rev Esp Quimioter; 2024 Feb; 37(1):69-77. PubMed ID: 37882320 [TBL] [Abstract][Full Text] [Related]
14. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675 [TBL] [Abstract][Full Text] [Related]
15. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ; J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of the newly approved antimicrobial agent Cefiderocol against Carbapenem resistant Gram negative clinical isolates. Khanchandani H; Chaudhury M; Rao MS; Ramakrishna N; Venkataramana B; Chaudhury A Indian J Med Microbiol; 2024; 48():100556. PubMed ID: 38447857 [TBL] [Abstract][Full Text] [Related]
18. [Discovery of a New Siderophore Cephalosporin, Cefiderocol]. Yamano Y Yakugaku Zasshi; 2024; 144(6):627-631. PubMed ID: 38825471 [TBL] [Abstract][Full Text] [Related]
19. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria. Ong'uti S; Czech M; Robilotti E; Holubar M Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098 [TBL] [Abstract][Full Text] [Related]
20. Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience. Piccica M; Spinicci M; Botta A; Bianco V; Lagi F; Graziani L; Faragona A; Parrella R; Giani T; Bartolini A; Morroni G; Bernardo M; Rossolini GM; Tavio M; Giacometti A; Bartoloni A J Antimicrob Chemother; 2023 Nov; 78(11):2752-2761. PubMed ID: 37807834 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]